

Table of Contents

Number	Title
1	Table 00: Comments
2	Table 01: Study population and enrolment information
3	Table 02: Patients by region, country, and cohort
4	Table 03 : Demographic Characteristics
5	Table 04 : Care setting , Type of AF and Insurance
6	Table 05 : Vital signs and life style
7	Table 06 : Clinical History
8	Table 07 : Treatment for stroke prophylaxis
9	Table 08: Treatment
10	Table 09 : Risk scores
11	Table 10: Treatment at baseline by CHA2DS2-VASc score
12	Table 11: Treatment at baseline by HAS-BLED score
13	Table 12: INR values and time in therapeutic range (TTR) during the first year of follow-up Cohorts 1 to 4
14	Table 13 :Event rates during the first year of follow-up Cohorts 1 to 4
15	Table 14: Cause of death during the first year of follow-up Cohorts 1 to 4
16	Table 15: Type of stroke during the first year of follow-up Cohorts 1 to 4
17	Table 16 : Mortality rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
18	Table 17 : Stroke/SE rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
19	Table 18 : Major bleeding rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4

Table 00: Comments

- 1 The data was extracted from the GARFIELD-AF registry database on 28 JUL 2016
- 2 The data includes retrospective patients in cohort 1 and prospective patients in cohort 1, 2, 3, 4 and 5
- 3 The variable 'Congestive heart failure' was split into 'History of CHF' and 'Current CHF' in cohorts 3, 4 and 5. History of and/or current CHF were used to identify CHF in cohort 3, 4 and 5 patients (Table 6)
- 4 The variable 'Coronary artery disease' was split into 'History of CAD' and 'Current CAD' in cohorts 3, 4 and 5. History of and/or current CAD were used to identify CAD in cohort 3, 4 and 5 patients (Table 6)
- 5 The variable 'Other thromboembolism' is not recorded for patients in cohort 3, 4 and 5
- 6 The option 'None' was added in the CRF for the 'Chronic renal disease' field in cohort 3, 4 and 5. The percentages for the variable 'Moderate to severe CKD' are estimated assuming that patients with 'unknown' stage of CKD are without 'Moderate to severe CKD' (Table 6)
- 7 Table 7 describes the baseline treatment for stroke prophylaxis. For each treatment group identifier options are mutually exclusive. The option 'unknown' includes combination of treatments
- 8 Table 8 shows the baseline treatment for stroke prophylaxis with non mutually exclusive groups
- 9 Table 12 shows INR values and TTR for patients treated with VKA±AP at baseline. INR readings during the first year of follow-up were included in the analysis. Values less than 0.8 or greater than 20 were removed since these values may not be plausible. Patients on VKA±AP at enrolment but with fewer than three readings during the follow-up were excluded from the analysis. Patient-level TTR was estimated by linear interpolation according to Rosendaal et al (1993), using 2.0-3.0 as the target INR range. TTR was estimated using INR readings until discontinuation or interruption of VKA or the end of follow-up. In addition, TTR was estimated between two consecutive INR readings only if the interval did not exceed 90 days.
- 10 Tables 13 and 14 describe events during the first year of follow-up for patients in cohorts 1-4. Only the first occurrence of each event was taken into account.
- 11 Table 13 Congestive heart failure during the follow-up includes new congestive heart failure or worsening of pre-existing congestive heart failure.

Table 01: Study population and enrolment information
Full Analysis Dataset : ARGENTINA

Number of prospective patients (C1+C2+C3+C4+C5)	1031
Number of enrolling sites	24
Number of enrolling countries	1
Enrolment period	30AUG2012 - 26JUL2016
Duration of enrolment (months)	46.9

Table 02: Patients by region, country, and cohort
Full Analysis Dataset : ARGENTINA

Region	Country	Cohort 2 (N=306)	Cohort 3 (N=325)	Cohort 4 (N=213)	Cohort 5 (N=187)	Total Prospective patients Cohorts 1 to 5 (N=1031)	Total Prospective patients Cohorts 1 to 4 (N=844)
Latin America	Argentina	306	325	213	187	1031	844

Table 03 : Demographic Characteristics
Full Analysis Dataset : ARGENTINA

Variable	Statistics	Cohort 2 (N=306) (n %)	Cohort 3 (N=325) (n %)	Cohort 4 (N=213) (n %)	Cohort 5 (N=187) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1031)	Total Prospective patients Cohorts 1 to 4 (N=844)
Sex, n(%)	n (missing)	306 (0)	325 (0)	213 (0)	187 (0)	1031 (0)	844 (0)
	Male	177 (57.8)	179 (55.1)	107 (50.2)	109 (58.3)	572 (55.5)	463 (54.9)
	Female	129 (42.2)	146 (44.9)	106 (49.8)	78 (41.7)	459 (44.5)	381 (45.1)
Age at Diagnosis (Years)	n (missing)	306 (0)	325 (0)	213 (0)	187 (0)	1031 (0)	844 (0)
	Mean (SD)	69.6 (10.8)	69.6 (11.2)	70.0 (12.2)	70.3 (10.6)	69.8 (11.2)	69.7 (11.3)
	Median (IQR)	71.0 (63.0 to 78.0)	70.0 (63.0 to 78.0)	71.0 (62.0 to 81.0)	71.0 (63.0 to 79.0)	70.0 (63.0 to 78.0)	70.0 (63.0 to 78.0)
	Min to Max	25 to 92	29 to 101	29 to 91	42 to 93	25 to 101	25 to 101
Age Group, n(%)	n (missing)	306 (0)	325 (0)	213 (0)	187 (0)	1031 (0)	844 (0)
	<65	91 (29.7)	96 (29.5)	65 (30.5)	59 (31.6)	311 (30.2)	252 (29.9)
	65-74	109 (35.6)	118 (36.3)	60 (28.2)	56 (29.9)	343 (33.3)	287 (34.0)
	>=75	106 (34.6)	111 (34.2)	88 (41.3)	72 (38.5)	377 (36.6)	305 (36.1)
Time since AF Diagnosis (Weeks)	n (missing)	223 (83)	193 (132)	137 (76)	135 (52)	688 (343)	553 (291)
	Mean (SD)	1.94 (1.76)	1.69 (1.63)	1.64 (1.71)	1.62 (1.74)	1.75 (1.71)	1.78 (1.71)
	Median (IQR)	1.40 (0.50 to 2.80)	1.00 (0.40 to 2.70)	0.80 (0.20 to 3.00)	0.70 (0.20 to 3.10)	1.00 (0.40 to 2.80)	1.10 (0.40 to 2.80)
	Min to Max	0.1 to 6.0	0.1 to 6.0	0.1 to 5.8	0.1 to 6.0	0.1 to 6.0	0.1 to 6.0
Race, n(%)	n (missing)	305 (0)	323 (0)	212 (0)	185 (0)	1025 (0)	840 (0)
	Caucasian	92 (30.2)	130 (40.2)	78 (36.8)	71 (38.4)	371 (36.2)	300 (35.7)
	Hispanic/Latino	213 (69.8)	193 (59.8)	133 (62.7)	114 (61.6)	653 (63.7)	539 (64.2)
	Asian (Not Chinese)	-	-	1 (0.5)	-	1 (0.1)	1 (0.1)

Table 03 : Demographic Characteristics
Full Analysis Dataset : ARGENTINA

Variable	Statistics	Cohort 2 (N=306) (n %)	Cohort 3 (N=325) (n %)	Cohort 4 (N=213) (n %)	Cohort 5 (N=187) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1031)	Total Prospective patients Cohorts 1 to 4 (N=844)
	Unknown	1	2	1	2	6	4
Region, n(%)	n (missing)	306 (0)	325 (0)	213 (0)	187 (0)	1031 (0)	844 (0)
	Latin America	306 (100.0)	325 (100.0)	213 (100.0)	187 (100.0)	1031 (100.0)	844 (100.0)

Table 04 : Care setting , Type of AF and Insurance
Full Analysis Dataset : ARGENTINA

Variable	Statistics	Cohort 2 (N=306) (n %)	Cohort 3 (N=325) (n %)	Cohort 4 (N=213) (n %)	Cohort 5 (N=187) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1031)	Total Prospective patients Cohorts 1 to 4 (N=844)
Care Setting	n (missing)	306 (0)	325 (0)	213 (0)	187 (0)	1031 (0)	844 (0)
Speciality at Diagnosis, n(%)							
	Internal Medicine	20 (6.5)	24 (7.4)	17 (8.0)	23 (12.3)	84 (8.1)	61 (7.2)
	Cardiology	260 (85.0)	283 (87.1)	193 (90.6)	158 (84.5)	894 (86.7)	736 (87.2)
	Neurology	1 (0.3)	-	-	1 (0.5)	2 (0.2)	1 (0.1)
	Primary Care/General Practice	25 (8.2)	18 (5.5)	3 (1.4)	5 (2.7)	51 (4.9)	46 (5.5)
Care Setting	n (missing)	306 (0)	325 (0)	213 (0)	187 (0)	1031 (0)	844 (0)
Location at Diagnosis, n(%)							
	Hospital	116 (37.9)	136 (41.8)	78 (36.6)	75 (40.1)	405 (39.3)	330 (39.1)
	Office	88 (28.8)	82 (25.2)	53 (24.9)	38 (20.3)	261 (25.3)	223 (26.4)
	Anticoagulation clinic/thrombosi s centre	3 (1.0)	2 (0.6)	3 (1.4)	3 (1.6)	11 (1.1)	8 (0.9)
	Emergency room	99 (32.4)	105 (32.3)	79 (37.1)	71 (38.0)	354 (34.3)	283 (33.5)
Type of AF Diagnosed, n(%)	n (missing)	306 (0)	325 (0)	213 (0)	187 (0)	1031 (0)	844 (0)
	Permanent	68 (22.2)	52 (16.0)	43 (20.2)	16 (8.6)	179 (17.4)	163 (19.3)
	Persistent	18 (5.9)	19 (5.8)	17 (8.0)	18 (9.6)	72 (7.0)	54 (6.4)
	Paroxysmal	57 (18.6)	67 (20.6)	44 (20.7)	44 (23.5)	212 (20.6)	168 (19.9)
	New	163 (53.3)	187 (57.5)	109 (51.2)	109 (58.3)	568 (55.1)	459 (54.4)

Table 04 : Care setting , Type of AF and Insurance
Full Analysis Dataset : ARGENTINA

Variable	Statistics	Cohort 2 (N=306) (n %)	Cohort 3 (N=325) (n %)	Cohort 4 (N=213) (n %)	Cohort 5 (N=187) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1031)	Total Prospective patients Cohorts 1 to 4 (N=844)
Treatment Costs, n(%)	n (missing)	303 (0)	325 (0)	212 (0)	187 (0)	1027 (0)	840 (0)
	Public insurance	43 (14.2)	35 (10.8)	22 (10.4)	44 (23.5)	144 (14.0)	100 (11.9)
	Private (insurance)	221 (72.9)	199 (61.2)	120 (56.6)	94 (50.3)	634 (61.7)	540 (64.3)
	Private (out of pocket)	12 (4.0)	15 (4.6)	4 (1.9)	4 (2.1)	35 (3.4)	31 (3.7)
	Combination	27 (8.9)	76 (23.4)	66 (31.1)	45 (24.1)	214 (20.8)	169 (20.1)
	Unknown	3	-	1	-	4	4
Treatment Sector, n(%)	n (missing)	306 (0)	325 (0)	213 (0)	187 (0)	1031 (0)	844 (0)
	In the public sector	43 (14.1)	38 (11.7)	20 (9.4)	20 (10.7)	121 (11.7)	101 (12.0)
	In the private sector	263 (85.9)	287 (88.3)	193 (90.6)	167 (89.3)	910 (88.3)	743 (88.0)

Table 05 : Vital signs and life style
Full Analysis Dataset : ARGENTINA

Variable	Statistics	Cohort 2 (N=306) (n %)	Cohort 3 (N=325) (n %)	Cohort 4 (N=213) (n %)	Cohort 5 (N=187) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1031)	Total Prospective patients Cohorts 1 to 4 (N=844)
Height (cm)	n (missing)	248 (58)	261 (64)	150 (63)	130 (57)	789 (242)	659 (185)
	Mean (SD)	166.4 (9.4)	166.8 (10.1)	166.5 (10.2)	168.7 (10.7)	166.9 (10.0)	166.6 (9.9)
	Median (IQR)	165.0 (160.0 to 172.0)	166.0 (160.0 to 175.0)	165.0 (160.0 to 174.0)	168.0 (160.0 to 176.0)	166.0 (160.0 to 174.0)	165.0 (160.0 to 174.0)
	Min to Max	141 to 192	135 to 195	142 to 196	143 to 195	135 to 196	135 to 196
Weight (kg)	n (missing)	248 (58)	261 (64)	150 (63)	130 (57)	789 (242)	659 (185)
	Mean (SD)	80.3 (19.7)	82.3 (17.2)	82.0 (18.3)	82.5 (16.5)	81.6 (18.1)	81.5 (18.4)
	Median (IQR)	80.0 (68.0 to 90.0)	82.0 (70.0 to 92.0)	78.5 (68.0 to 94.0)	83.0 (70.0 to 92.0)	80.0 (69.0 to 92.0)	80.0 (69.0 to 92.0)
	Min to Max	40 to 227	32 to 140	50 to 130	45 to 126	32 to 227	32 to 227
BMI (kg/m ²)	n (missing)	248 (58)	261 (64)	150 (63)	130 (57)	789 (242)	659 (185)
	Mean (SD)	28.8 (5.6)	29.5 (5.6)	29.4 (5.4)	28.9 (5.1)	29.2 (5.5)	29.3 (5.6)
	Median (IQR)	28.0 (25.0 to 32.0)	29.0 (25.0 to 33.0)	28.0 (26.0 to 33.0)	28.0 (26.0 to 31.0)	28.0 (25.0 to 32.0)	28.0 (25.0 to 32.0)
	Min to Max	18 to 62	18 to 50	20 to 48	20 to 50	18 to 62	18 to 62
BMI Category, n(%)	n (missing)	248 (58)	261 (64)	150 (63)	130 (57)	789 (242)	659 (185)
	<19	3 (1.2)	1 (0.4)	-	-	4 (0.5)	4 (0.6)
	19-<25	63 (25.4)	54 (20.7)	27 (18.0)	27 (20.8)	171 (21.7)	144 (21.9)
	25-<30	88 (35.5)	97 (37.2)	64 (42.7)	61 (46.9)	310 (39.3)	249 (37.8)
	30-<40	88 (35.5)	96 (36.8)	52 (34.7)	36 (27.7)	272 (34.5)	236 (35.8)
	>=40	6 (2.4)	13 (5.0)	7 (4.7)	6 (4.6)	32 (4.1)	26 (3.9)
Pulse (bpm)	n (missing)	288 (18)	318 (7)	201 (12)	178 (9)	985 (46)	807 (37)
	Mean (SD)	94.2 (28.7)	97.6 (32.4)	98.6 (31.1)	101.5 (34.1)	97.5 (31.5)	96.6 (30.8)
	Median (IQR)	87.0 (70.0 to 115.0)	90.0 (70.0 to 122.0)	90.0 (72.0 to 120.0)	94.5 (72.0 to 130.0)	90.0 (72.0 to 120.0)	90.0 (70.0 to 120.0)
	Min to Max	30 to 170	40 to 250	48 to 170	22 to 180	22 to 250	30 to 250

Table 05 : Vital signs and life style
Full Analysis Dataset : ARGENTINA

Variable	Statistics	Cohort 2 (N=306) (n %)	Cohort 3 (N=325) (n %)	Cohort 4 (N=213) (n %)	Cohort 5 (N=187) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1031)	Total Prospective patients Cohorts 1 to 4 (N=844)
Systolic BP (mm Hg)	n (missing)	283 (23)	314 (11)	200 (13)	171 (16)	968 (63)	797 (47)
	Mean (SD)	129.6 (16.5)	131.8 (18.6)	131.5 (22.5)	128.7 (19.1)	130.5 (19.0)	130.9 (19.0)
	Median (IQR)	130.0 (120.0 to 140.0)	130.0 (120.0 to 140.0)	130.0 (120.0 to 145.0)	130.0 (118.0 to 140.0)	130.0 (120.0 to 140.0)	130.0 (120.0 to 140.0)
	Min to Max	80 to 200	80 to 200	86 to 200	80 to 180	80 to 200	80 to 200
Diastolic BP (mm Hg)	n (missing)	283 (23)	314 (11)	200 (13)	171 (16)	968 (63)	797 (47)
	Mean (SD)	78.5 (11.1)	79.2 (11.8)	77.4 (14.2)	76.0 (12.0)	78.0 (12.2)	78.5 (12.3)
	Median (IQR)	80.0 (70.0 to 85.0)	80.0 (70.0 to 85.0)	77.5 (69.5 to 88.5)	76.0 (68.0 to 84.0)	80.0 (70.0 to 85.0)	80.0 (70.0 to 85.0)
	Min to Max	40 to 120	40 to 130	50 to 120	50 to 110	40 to 130	40 to 130
LVEF (%)	n (missing)	159 (147)	143 (182)	88 (125)	74 (113)	464 (567)	390 (454)
	Mean (SD)	51.8 (12.0)	53.0 (12.6)	52.6 (12.2)	55.6 (13.3)	53.0 (12.4)	52.5 (12.2)
	Median (IQR)	54.0 (45.0 to 60.0)	55.0 (45.0 to 63.0)	55.0 (45.0 to 61.0)	60.0 (48.0 to 65.0)	55.0 (45.0 to 61.0)	55.0 (45.0 to 60.0)
	Min to Max	17 to 75	20 to 76	26 to 74	20 to 81	17 to 81	17 to 76
LVEF Category, n (n(%))	n (missing)	159 (147)	143 (182)	88 (125)	74 (113)	464 (567)	390 (454)
	<40%	25 (15.7)	20 (14.0)	15 (17.0)	9 (12.2)	69 (14.9)	60 (15.4)
	>=40%	134 (84.3)	123 (86.0)	73 (83.0)	65 (87.8)	395 (85.1)	330 (84.6)
History of Hypertension, n(%)	n (missing)	306 (0)	324 (0)	211 (0)	185 (0)	1026 (0)	841 (0)
	No	51 (16.7)	63 (19.4)	41 (19.4)	50 (27.0)	205 (20.0)	155 (18.4)
	Yes	255 (83.3)	261 (80.6)	170 (80.6)	135 (73.0)	821 (80.0)	686 (81.6)

Table 05 : Vital signs and life style
Full Analysis Dataset : ARGENTINA

Variable	Statistics	Cohort 2 (N=306) (n %)	Cohort 3 (N=325) (n %)	Cohort 4 (N=213) (n %)	Cohort 5 (N=187) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1031)	Total Prospective patients Cohorts 1 to 4 (N=844)
	Unknown	-	1	2	2	5	3
Alcohol Consumption, n(%)	n (missing)	264 (0)	274 (0)	189 (0)	184 (0)	911 (0)	727 (0)
	Abstinent	151 (57.2)	204 (74.5)	116 (61.4)	116 (63.0)	587 (64.4)	471 (64.8)
	Light	98 (37.1)	55 (20.1)	65 (34.4)	62 (33.7)	280 (30.7)	218 (30.0)
	Moderate	15 (5.7)	14 (5.1)	8 (4.2)	4 (2.2)	41 (4.5)	37 (5.1)
	Heavy	-	1 (0.4)	-	2 (1.1)	3 (0.3)	1 (0.1)
	Unknown	42	51	24	3	120	117
Smoker, n(%)	n (missing)	286 (0)	322 (0)	212 (0)	186 (0)	1006 (0)	820 (0)
	No	184 (64.3)	214 (66.5)	144 (67.9)	106 (57.0)	648 (64.4)	542 (66.1)
	Ex-smoker	80 (28.0)	75 (23.3)	46 (21.7)	57 (30.6)	258 (25.6)	201 (24.5)
	Current smoker	22 (7.7)	33 (10.2)	22 (10.4)	23 (12.4)	100 (9.9)	77 (9.4)
	Unknown	20	3	1	1	25	24

Table 06 : Clinical History
Full Analysis Dataset : ARGENTINA

Variable	Statistics	Cohort 2 (N=306) (n %)	Cohort 3 (N=325) (n %)	Cohort 4 (N=213) (n %)	Cohort 5 (N=187) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1031)	Total Prospective patients Cohorts 1 to 4 (N=844)
Congestive heart failure, n(%)	n (missing)	306 (0)	325 (0)	213 (0)	187 (0)	1031 (0)	844 (0)
	No	247 (80.7)	257 (79.1)	178 (83.6)	172 (92.0)	854 (82.8)	682 (80.8)
	Yes	59 (19.3)	68 (20.9)	35 (16.4)	15 (8.0)	177 (17.2)	162 (19.2)
Congestive Heart Failure NYHA Class, n(%)	n (missing)	59 (247)	63 (257)	29 (178)	13 (172)	164 (854)	151 (682)
	I	10 (16.9)	15 (23.8)	3 (10.3)	1 (7.7)	29 (17.7)	28 (18.5)
	II	32 (54.2)	22 (34.9)	11 (37.9)	4 (30.8)	69 (42.1)	65 (43.0)
	III	13 (22.0)	19 (30.2)	12 (41.4)	7 (53.8)	51 (31.1)	44 (29.1)
	IV	4 (6.8)	7 (11.1)	3 (10.3)	1 (7.7)	15 (9.1)	14 (9.3)
	Unknown	-	5	6	2	13	11
Coronary artery disease, n(%)	n (missing)	306 (0)	325 (0)	213 (0)	187 (0)	1031 (0)	844 (0)
	No	262 (85.6)	258 (79.4)	172 (80.8)	162 (86.6)	854 (82.8)	692 (82.0)
	Yes	44 (14.4)	67 (20.6)	41 (19.2)	25 (13.4)	177 (17.2)	152 (18.0)
Acute coronary syndrome, n(%)	n (missing)	306 (0)	322 (0)	212 (0)	187 (0)	1027 (0)	840 (0)
	No	273 (89.2)	284 (88.2)	184 (86.8)	165 (88.2)	906 (88.2)	741 (88.2)
	Yes	33 (10.8)	38 (11.8)	28 (13.2)	22 (11.8)	121 (11.8)	99 (11.8)
	Unknown	-	3	1	-	4	4
Carotid Occlusive Disease, n(%)	n (missing)	306 (0)	324 (0)	205 (0)	179 (0)	1014 (0)	835 (0)
	No	297 (97.1)	318 (98.1)	203 (99.0)	174 (97.2)	992 (97.8)	818 (98.0)

Table 06 : Clinical History
Full Analysis Dataset : ARGENTINA

Variable	Statistics	Cohort 2 (N=306) (n %)	Cohort 3 (N=325) (n %)	Cohort 4 (N=213) (n %)	Cohort 5 (N=187) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1031)	Total Prospective patients Cohorts 1 to 4 (N=844)
	Yes	9 (2.9)	6 (1.9)	2 (1.0)	5 (2.8)	22 (2.2)	17 (2.0)
	Unknown	-	1	8	8	17	9
PE or DVT, n(%)	n (missing)	306 (0)	325 (0)	213 (0)	186 (0)	1030 (0)	844 (0)
	No	299 (97.7)	321 (98.8)	209 (98.1)	183 (98.4)	1012 (98.3)	829 (98.2)
	Yes	7 (2.3)	4 (1.2)	4 (1.9)	3 (1.6)	18 (1.7)	15 (1.8)
	Unknown	-	-	-	1	1	-
Other Thromboemboli sm, n(%)	n (missing)	306 (0)	0 (325)	0 (213)	0 (187)	306 (725)	306 (538)
	No	305 (99.7)	-	-	-	305 (99.7)	305 (99.7)
	Yes	1 (0.3)	-	-	-	1 (0.3)	1 (0.3)
Systemic Embolization, n(%)	n (missing)	306 (0)	325 (0)	213 (0)	186 (0)	1030 (0)	844 (0)
	No	305 (99.7)	322 (99.1)	212 (99.5)	186 (100.0)	1025 (99.5)	839 (99.4)
	Yes	1 (0.3)	3 (0.9)	1 (0.5)	-	5 (0.5)	5 (0.6)
	Unknown	-	-	-	1	1	-
Coronary Artery Bypass Graft, n(%)	n (missing)	306 (0)	325 (0)	213 (0)	187 (0)	1031 (0)	844 (0)
	No	291 (95.1)	311 (95.7)	205 (96.2)	181 (96.8)	988 (95.8)	807 (95.6)
	Yes	15 (4.9)	14 (4.3)	8 (3.8)	6 (3.2)	43 (4.2)	37 (4.4)
Stroke/TIA, n(%)	n (missing)	306 (0)	325 (0)	213 (0)	187 (0)	1031 (0)	844 (0)
	No	283 (92.5)	306 (94.2)	194 (91.1)	174 (93.0)	957 (92.8)	783 (92.8)

Table 06 : Clinical History
Full Analysis Dataset : ARGENTINA

Variable	Statistics	Cohort 2 (N=306) (n %)	Cohort 3 (N=325) (n %)	Cohort 4 (N=213) (n %)	Cohort 5 (N=187) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1031)	Total Prospective patients Cohorts 1 to 4 (N=844)
	Yes	23 (7.5)	19 (5.8)	19 (8.9)	13 (7.0)	74 (7.2)	61 (7.2)
Stroke, n(%)	n (missing)	306 (0)	325 (0)	213 (0)	187 (0)	1031 (0)	844 (0)
	No	292 (95.4)	310 (95.4)	200 (93.9)	179 (95.7)	981 (95.2)	802 (95.0)
	Yes	14 (4.6)	15 (4.6)	13 (6.1)	8 (4.3)	50 (4.8)	42 (5.0)
History of Bleeding, n(%)	n (missing)	306 (0)	325 (0)	213 (0)	186 (0)	1030 (0)	844 (0)
	No	281 (91.8)	318 (97.8)	207 (97.2)	181 (97.3)	987 (95.8)	806 (95.5)
	Yes	25 (8.2)	7 (2.2)	6 (2.8)	5 (2.7)	43 (4.2)	38 (4.5)
	Unknown	-	-	-	1	1	-
Hypercholester olaemia, n(%)	n (missing)	306 (0)	312 (0)	191 (0)	173 (0)	982 (0)	809 (0)
	No	188 (61.4)	200 (64.1)	118 (61.8)	94 (54.3)	600 (61.1)	506 (62.5)
	Yes	118 (38.6)	112 (35.9)	73 (38.2)	79 (45.7)	382 (38.9)	303 (37.5)
	Unknown	-	13	22	14	49	35
Diabetes, n(%)	n (missing)	306 (0)	325 (0)	213 (0)	187 (0)	1031 (0)	844 (0)
	No	246 (80.4)	267 (82.2)	172 (80.8)	159 (85.0)	844 (81.9)	685 (81.2)
	Type I	3 (1.0)	2 (0.6)	7 (3.3)	5 (2.7)	17 (1.6)	12 (1.4)
	Type II	57 (18.6)	56 (17.2)	34 (16.0)	23 (12.3)	170 (16.5)	147 (17.4)
Diabetes, n(%)	n (missing)	306 (0)	325 (0)	213 (0)	187 (0)	1031 (0)	844 (0)
	No	246 (80.4)	267 (82.2)	172 (80.8)	159 (85.0)	844 (81.9)	685 (81.2)
	Yes	60 (19.6)	58 (17.8)	41 (19.2)	28 (15.0)	187 (18.1)	159 (18.8)
Cirrhosis, n(%)	n (missing)	306 (0)	319 (0)	211 (0)	172 (0)	1008 (0)	836 (0)
	No	306 (100.0)	319 (100.0)	211 (100.0)	172 (100.0)	1008 (100.0)	836 (100.0)
	Unknown	-	6	2	15	23	8

Table 06 : Clinical History
Full Analysis Dataset : ARGENTINA

Variable	Statistics	Cohort 2 (N=306) (n %)	Cohort 3 (N=325) (n %)	Cohort 4 (N=213) (n %)	Cohort 5 (N=187) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1031)	Total Prospective patients Cohorts 1 to 4 (N=844)
Dementia, n(%)	n (missing)	306 (0)	324 (0)	213 (0)	187 (0)	1030 (0)	843 (0)
	No	301 (98.4)	324 (100.0)	208 (97.7)	184 (98.4)	1017 (98.7)	833 (98.8)
	Yes	5 (1.6)	-	5 (2.3)	3 (1.6)	13 (1.3)	10 (1.2)
	Unknown	-	1	-	-	1	1
Hyperthyroidism, n(%)	n (missing)	306 (0)	322 (0)	210 (0)	184 (0)	1022 (0)	838 (0)
	No	303 (99.0)	318 (98.8)	210 (100.0)	184 (100.0)	1015 (99.3)	831 (99.2)
	Yes	3 (1.0)	4 (1.2)	-	-	7 (0.7)	7 (0.8)
	Unknown	-	3	3	3	9	6
Hypothyroidism, n(%)	n (missing)	306 (0)	320 (0)	209 (0)	184 (0)	1019 (0)	835 (0)
	No	273 (89.2)	286 (89.4)	174 (83.3)	162 (88.0)	895 (87.8)	733 (87.8)
	Yes	33 (10.8)	34 (10.6)	35 (16.7)	22 (12.0)	124 (12.2)	102 (12.2)
	Unknown	-	5	4	3	12	9
Vascular Disease, n(%)	n (missing)	306 (0)	325 (0)	212 (1)	187 (0)	1030 (1)	843 (1)
	No	262 (85.6)	267 (82.2)	178 (84.0)	161 (86.1)	868 (84.3)	707 (83.9)
	Yes	44 (14.4)	58 (17.8)	34 (16.0)	26 (13.9)	162 (15.7)	136 (16.1)
Moderate to Severe CKD, n(%)	n (missing)	306 (0)	325 (0)	212 (1)	187 (0)	1030 (1)	843 (1)
	No	287 (93.8)	306 (94.2)	203 (95.8)	185 (98.9)	981 (95.2)	796 (94.4)
	Yes	19 (6.2)	19 (5.8)	9 (4.2)	2 (1.1)	49 (4.8)	47 (5.6)

Table 07 : Treatment for stroke prophylaxis
Full Analysis Dataset : ARGENTINA

Variable	Statistics	Cohort 2 (N=306) (n %)	Cohort 3 (N=325) (n %)	Cohort 4 (N=213) (n %)	Cohort 5 (N=187) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1031)	Total Prospective patients Cohorts 1 to 4 (N=844)
Baseline Treatment, n(%)	n (missing)	305 (0)	324 (0)	212 (0)	186 (0)	1027 (0)	841 (0)
	VKA	80 (26.2)	84 (25.9)	46 (21.7)	57 (30.6)	267 (26.0)	210 (25.0)
	VKA+AP	65 (21.3)	32 (9.9)	29 (13.7)	13 (7.0)	139 (13.5)	126 (15.0)
	FXA	12 (3.9)	21 (6.5)	24 (11.3)	20 (10.8)	77 (7.5)	57 (6.8)
	FXA+AP	8 (2.6)	6 (1.9)	2 (0.9)	10 (5.4)	26 (2.5)	16 (1.9)
	DTI	8 (2.6)	16 (4.9)	22 (10.4)	14 (7.5)	60 (5.8)	46 (5.5)
	DTI+AP	6 (2.0)	11 (3.4)	3 (1.4)	-	20 (1.9)	20 (2.4)
	AP	94 (30.8)	71 (21.9)	41 (19.3)	32 (17.2)	238 (23.2)	206 (24.5)
	NONE	32 (10.5)	83 (25.6)	45 (21.2)	40 (21.5)	200 (19.5)	160 (19.0)
	Unknown	1	1	1	1	4	3
	VKA±AP	145 (47.5)	116 (35.8)	75 (35.4)	70 (37.6)	406 (39.5)	336 (40.0)
	FXA±AP	20 (6.6)	27 (8.3)	26 (12.3)	30 (16.1)	103 (10.0)	73 (8.7)
	DTI±AP	14 (4.6)	27 (8.3)	25 (11.8)	14 (7.5)	80 (7.8)	66 (7.8)
	FXA/DTI	20 (6.6)	37 (11.4)	46 (21.7)	34 (18.3)	137 (13.3)	103 (12.2)
	FXA/DTI+AP	14 (4.6)	17 (5.2)	5 (2.4)	10 (5.4)	46 (4.5)	36 (4.3)
	FXA/DTI±AP	34 (11.1)	54 (16.7)	51 (24.1)	44 (23.7)	183 (17.8)	139 (16.5)
	AC	100 (32.8)	121 (37.3)	92 (43.4)	91 (48.9)	404 (39.3)	313 (37.2)
	AC+AP	79 (25.9)	49 (15.1)	34 (16.0)	23 (12.4)	185 (18.0)	162 (19.3)
	AC±AP	179 (58.7)	170 (52.5)	126 (59.4)	114 (61.3)	589 (57.4)	475 (56.5)

Table 08: Treatment
Full Analysis Dataset : ARGENTINA

	Cohort 2 (N=306) (n %)	Cohort 3 (N=325) (n %)	Cohort 4 (N=213) (n %)	Cohort 5 (N=187) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1031)	Total Prospective patients Cohorts 1 to 4 (N=844)
Anti-platelet (non mutually exclusive groups)						
ADP receptor/P2Y12 inhibitors	12 (3.9)	8 (2.5)	9 (4.2)	7 (3.7)	36 (3.5)	29 (3.4)
Cox inhibitors	-	14 (4.3)	9 (4.2)	1 (0.5)	24 (2.3)	23 (2.7)
ASA	166 (54.2)	101 (31.1)	71 (33.3)	50 (26.7)	388 (37.6)	338 (40.0)
Anticoagulant drugs (non mutually exclusive groups)						
VKA	146 (47.7)	117 (36.0)	75 (35.2)	70 (37.4)	408 (39.6)	338 (40.0)
FXa	21 (6.9)	28 (8.6)	26 (12.2)	31 (16.6)	106 (10.3)	75 (8.9)
DTI	14 (4.6)	27 (8.3)	25 (11.7)	15 (8.0)	81 (7.9)	66 (7.8)
Heparinoid	1 (0.3)	-	1 (0.5)	-	2 (0.2)	2 (0.2)
Heparins	19 (6.2)	29 (8.9)	8 (3.8)	11 (5.9)	67 (6.5)	56 (6.6)
Other	2 (0.7)	-	-	1 (0.5)	3 (0.3)	2 (0.2)

Table 09 : Risk scores
Full Analysis Dataset : ARGENTINA

Variable	Statistics	Cohort 2 (N=306) (n %)	Cohort 3 (N=325) (n %)	Cohort 4 (N=213) (n %)	Cohort 5 (N=187) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1031)	Total Prospective patients Cohorts 1 to 4 (N=844)
CHADS2 Score	n (missing)	300 (6)	319 (6)	211 (2)	184 (3)	1014 (17)	830 (14)
	Mean (SD)	1.8 (1.0)	1.7 (1.0)	1.8 (1.1)	1.5 (1.1)	1.7 (1.0)	1.8 (1.0)
	Median (IQR)	2.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)
	Min to Max	0 to 5	0 to 6	0 to 6	0 to 6	0 to 6	0 to 6
CHADS2 score categories, n(%)	n (missing)	300 (6)	319 (6)	211 (2)	184 (3)	1014 (17)	830 (14)
	0	15 (5.0)	24 (7.5)	16 (7.6)	23 (12.5)	78 (7.7)	55 (6.6)
	1	119 (39.7)	125 (39.2)	75 (35.5)	75 (40.8)	394 (38.9)	319 (38.4)
	2	104 (34.7)	113 (35.4)	74 (35.1)	61 (33.2)	352 (34.7)	291 (35.1)
	3	47 (15.7)	41 (12.9)	34 (16.1)	17 (9.2)	139 (13.7)	122 (14.7)
	4	9 (3.0)	14 (4.4)	8 (3.8)	5 (2.7)	36 (3.6)	31 (3.7)
	5	6 (2.0)	1 (0.3)	3 (1.4)	1 (0.5)	11 (1.1)	10 (1.2)
	6	-	1 (0.3)	1 (0.5)	2 (1.1)	4 (0.4)	2 (0.2)
CHA2DS2- VASc Score	n (missing)	300 (6)	319 (6)	210 (3)	183 (4)	1012 (19)	829 (15)
	Mean (SD)	3.1 (1.5)	3.1 (1.4)	3.2 (1.6)	2.8 (1.5)	3.1 (1.5)	3.1 (1.5)
	Median (IQR)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)
	Min to Max	0 to 8	0 to 9	0 to 9	0 to 8	0 to 9	0 to 9
CHA2DS2- VASc score categories, n(%)	n (missing)	300 (6)	319 (6)	210 (3)	183 (4)	1012 (19)	829 (15)
	0	4 (1.3)	3 (0.9)	7 (3.3)	8 (4.4)	22 (2.2)	14 (1.7)
	1	37 (12.3)	43 (13.5)	24 (11.4)	28 (15.3)	132 (13.0)	104 (12.5)
	2	75 (25.0)	75 (23.5)	40 (19.0)	41 (22.4)	231 (22.8)	190 (22.9)
	3	68 (22.7)	79 (24.8)	52 (24.8)	47 (25.7)	246 (24.3)	199 (24.0)
	4	62 (20.7)	70 (21.9)	48 (22.9)	39 (21.3)	219 (21.6)	180 (21.7)

Table 09 : Risk scores
Full Analysis Dataset : ARGENTINA

Variable	Statistics	Cohort 2 (N=306) (n %)	Cohort 3 (N=325) (n %)	Cohort 4 (N=213) (n %)	Cohort 5 (N=187) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1031)	Total Prospective patients Cohorts 1 to 4 (N=844)
	5	37 (12.3)	33 (10.3)	25 (11.9)	14 (7.7)	109 (10.8)	95 (11.5)
	6-9	17 (5.7)	16 (5.0)	14 (6.7)	6 (3.3)	53 (5.2)	47 (5.7)
HAS-BLED score	n (missing)	215 (91)	255 (70)	175 (38)	168 (19)	813 (218)	645 (199)
	Mean (SD)	1.5 (0.9)	1.4 (0.8)	1.4 (0.8)	1.3 (0.9)	1.4 (0.8)	1.4 (0.8)
	Median (IQR)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)
	Min to Max	0 to 4	0 to 4	0 to 4	0 to 4	0 to 4	0 to 4
HAS-BLED score categories, n(%)	n (missing)	215 (91)	255 (70)	175 (38)	168 (19)	813 (218)	645 (199)
	0	26 (12.1)	32 (12.5)	21 (12.0)	32 (19.0)	111 (13.7)	79 (12.2)
	1	83 (38.6)	109 (42.7)	82 (46.9)	74 (44.0)	348 (42.8)	274 (42.5)
	2	83 (38.6)	99 (38.8)	58 (33.1)	52 (31.0)	292 (35.9)	240 (37.2)
	3	22 (10.2)	13 (5.1)	13 (7.4)	8 (4.8)	56 (6.9)	48 (7.4)
	4	1 (0.5)	2 (0.8)	1 (0.6)	2 (1.2)	6 (0.7)	4 (0.6)

Table 10: Treatment at baseline by CHA2DS2-VASc score
Full Analysis Dataset : ARGENTINA

		VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
Cohort	CHA2DS2-VASc	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
Cohort 2	0	-	-	-	-	-	-	1	25	-	-	-	-	2	50	1	25	-
	1	5	13.5	4	10.8	2	5.4	2	5.4	4	10.8	-	-	15	40.5	5	13.5	-
	2	14	18.7	18	24	2	2.7	1	1.3	3	4	2	2.7	23	30.7	12	16	-
	3	21	31.3	11	16.4	4	6	2	3	-	-	2	3	21	31.3	6	9	1
	4	20	32.3	16	25.8	3	4.8	1	1.6	1	1.6	2	3.2	16	25.8	3	4.8	-
	5	13	35.1	8	21.6	-	-	1	2.7	-	-	-	-	11	29.7	4	10.8	-
	6-9	5	29.4	7	41.2	-	-	-	-	-	-	-	-	5	29.4	-	-	-
Cohort 3	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	100	-
	1	8	18.6	2	4.7	2	4.7	1	2.3	-	-	2	4.7	12	27.9	16	37.2	-
	2	23	30.7	5	6.7	4	5.3	1	1.3	5	6.7	3	4	14	18.7	20	26.7	-
	3	23	29.1	11	13.9	6	7.6	2	2.5	2	2.5	3	3.8	14	17.7	18	22.8	-
	4	20	28.6	8	11.4	6	8.6	2	2.9	5	7.1	2	2.9	14	20	13	18.6	-
	5	7	21.9	3	9.4	2	6.3	-	-	1	3.1	1	3.1	12	37.5	6	18.8	1
	6-9	2	12.5	3	18.8	-	-	-	-	3	18.8	-	-	3	18.8	5	31.3	-
Cohort 4	0	3	50	-	-	1	16.7	-	-	1	16.7	-	-	1	16.7	-	-	1
	1	2	8.3	-	-	3	12.5	-	-	3	12.5	-	-	7	29.2	9	37.5	-
	2	5	12.5	6	15	5	12.5	-	-	6	15	-	-	10	25	8	20	-
	3	18	34.6	4	7.7	4	7.7	-	-	6	11.5	1	1.9	9	17.3	10	19.2	-
	4	8	16.7	8	16.7	6	12.5	1	2.1	5	10.4	2	4.2	8	16.7	10	20.8	-
	5	6	24	6	24	4	16	1	4	1	4	-	-	3	12	4	16	-
	6-9	1	7.1	5	35.7	1	7.1	-	-	-	-	-	-	3	21.4	4	28.6	-
Cohort 5	0	2	25	-	-	1	12.5	1	12.5	1	12.5	-	-	-	-	3	37.5	-
	1	5	17.9	-	-	6	21.4	3	10.7	3	10.7	-	-	3	10.7	8	28.6	-
	2	12	29.3	3	7.3	8	19.5	2	4.9	1	2.4	-	-	8	19.5	7	17.1	-
	3	15	32.6	4	8.7	2	4.3	3	6.5	5	10.9	-	-	7	15.2	10	21.7	1
	4	15	38.5	2	5.1	1	2.6	1	2.6	2	5.1	-	-	9	23.1	9	23.1	-
	5	5	35.7	3	21.4	1	7.1	-	-	-	-	-	-	3	21.4	2	14.3	-
	6-9	2	33.3	1	16.7	-	-	-	-	1	16.7	-	-	1	16.7	1	16.7	-

Table 10: Treatment at baseline by CHA2DS2-VASc score
Full Analysis Dataset : ARGENTINA

Cohort	CHA2DS2-VASc	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
Total Prospective patients Cohorts 1 to 5	0	5	23.8	-	-	2	9.5	2	9.5	2	9.5	-	-	3	14.3	7	33.3	1
	1	20	15.2	6	4.5	13	9.8	6	4.5	10	7.6	2	1.5	37	28	38	28.8	-
	2	54	23.4	32	13.9	19	8.2	4	1.7	15	6.5	5	2.2	55	23.8	47	20.3	-
	3	77	31.6	30	12.3	16	6.6	7	2.9	13	5.3	6	2.5	51	20.9	44	18	2
	4	63	28.8	34	15.5	16	7.3	5	2.3	13	5.9	6	2.7	47	21.5	35	16	-
	5	31	28.7	20	18.5	7	6.5	2	1.9	2	1.9	1	0.9	29	26.9	16	14.8	1
	6-9	10	18.9	16	30.2	1	1.9	-	-	4	7.5	-	-	12	22.6	10	18.9	-
Total Prospective patients Cohorts 1 to 4	0	3	23.1	-	-	1	7.7	1	7.7	1	7.7	-	-	3	23.1	4	30.8	1
	1	15	14.4	6	5.8	7	6.7	3	2.9	7	6.7	2	1.9	34	32.7	30	28.8	-
	2	42	22.1	29	15.3	11	5.8	2	1.1	14	7.4	5	2.6	47	24.7	40	21.1	-
	3	62	31.3	26	13.1	14	7.1	4	2	8	4	6	3	44	22.2	34	17.2	1
	4	48	26.7	32	17.8	15	8.3	4	2.2	11	6.1	6	3.3	38	21.1	26	14.4	-
	5	26	27.7	17	18.1	6	6.4	2	2.1	2	2.1	1	1.1	26	27.7	14	14.9	1
	6-9	8	17	15	31.9	1	2.1	-	-	3	6.4	-	-	11	23.4	9	19.1	-

Table 11: Treatment at baseline by HAS-BLED score
Full Analysis Dataset : ARGENTINA

Cohort	HAS-BLED	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	
Cohort 2	0	12	46.2	-	-	2	7.7	-	-	3	11.5	-	-	-	-	9	34.6	-
	1	33	40.2	10	12.2	6	7.3	3	3.7	3	3.7	2	2.4	17	20.7	8	9.8	1
	2	9	10.8	36	43.4	1	1.2	4	4.8	1	1.2	-	-	30	36.1	2	2.4	-
	3	4	18.2	8	36.4	-	-	-	-	-	-	-	-	9	40.9	1	4.5	-
	4-9	-	-	-	-	-	-	-	-	-	-	-	-	1	100	-	-	-
Cohort 3	0	13	40.6	-	-	3	9.4	-	-	3	9.4	-	-	-	-	13	40.6	-
	1	40	36.7	6	5.5	9	8.3	1	0.9	9	8.3	2	1.8	15	13.8	27	24.8	-
	2	16	16.2	17	17.2	5	5.1	5	5.1	3	3	5	5.1	26	26.3	22	22.2	-
	3	1	8.3	1	8.3	-	-	-	-	-	-	3	25	7	58.3	-	-	1
	4-9	-	-	1	50	-	-	-	-	-	-	-	-	1	50	-	-	-
Cohort 4	0	7	35	-	-	5	25	-	-	2	10	-	-	-	-	6	30	1
	1	22	26.8	8	9.8	10	12.2	-	-	13	15.9	1	1.2	9	11	19	23.2	-
	2	7	12.1	11	19	3	5.2	2	3.4	1	1.7	2	3.4	24	41.4	8	13.8	-
	3	1	7.7	7	53.8	-	-	-	-	-	-	-	-	1	7.7	4	30.8	-
	4-9	-	-	-	-	-	-	-	-	-	-	-	-	1	100	-	-	-
Cohort 5	0	10	31.3	-	-	9	28.1	-	-	3	9.4	-	-	-	-	10	31.3	-
	1	32	43.8	4	5.5	6	8.2	3	4.1	6	8.2	-	-	4	5.5	18	24.7	1
	2	9	17.3	5	9.6	2	3.8	6	11.5	1	1.9	-	-	22	42.3	7	13.5	-
	3	3	37.5	2	25	-	-	-	-	1	12.5	-	-	1	12.5	1	12.5	-
	4-9	-	-	-	-	-	-	-	-	-	-	-	-	2	100	-	-	-
Total Prospective patients Cohorts 1 to 5	0	42	38.2	-	-	19	17.3	-	-	11	10	-	-	-	-	38	34.5	1
	1	127	36.7	28	8.1	31	9	7	2	31	9	5	1.4	45	13	72	20.8	2
	2	41	14	69	23.6	11	3.8	17	5.8	6	2.1	7	2.4	102	34.9	39	13.4	-
	3	9	16.4	18	32.7	-	-	-	-	1	1.8	3	5.5	18	32.7	6	10.9	1

Table 11: Treatment at baseline by HAS-BLED score
Full Analysis Dataset : ARGENTINA

Cohort	HAS-BLED	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
Total Prospective patients Cohorts 1 to 4	4-9	-	-	1	16.7	-	-	-	-	-	-	-	-	5	83.3	-	-	-
	0	32	41	-	-	10	12.8	-	-	8	10.3	-	-	-	-	28	35.9	1
	1	95	34.8	24	8.8	25	9.2	4	1.5	25	9.2	5	1.8	41	15	54	19.8	1
	2	32	13.3	64	26.7	9	3.8	11	4.6	5	2.1	7	2.9	80	33.3	32	13.3	-
	3	6	12.8	16	34	-	-	-	-	-	-	3	6.4	17	36.2	5	10.6	1
	4-9	-	-	1	25	-	-	-	-	-	-	-	-	3	75	-	-	-

**Table 12: INR values and time in therapeutic range (TTR) during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : ARGENTINA**

Variable	Statistics	Cohort 2 (N=145) (n %)	Cohort 3 (N=116) (n %)	Cohort 4 (N=75) (n %)	Total Prospective patients Cohorts 1 to 4 (N=336)
TTR value, n(%)	n (missing)	49 (96)	40 (76)	18 (57)	107 (229)
	<65	33 (67.3)	31 (77.5)	12 (66.7)	76 (71.0)
	>=65	16 (32.7)	9 (22.5)	6 (33.3)	31 (29.0)
TTR	n (missing)	49 (96)	40 (76)	18 (57)	107 (229)
	Mean (SD)	52.2 (27.0)	42.1 (26.8)	47.9 (29.2)	47.7 (27.4)
	Median (IQR)	54.9 (33.5 to 70.1)	37.6 (20.7 to 61.0)	44.2 (20.8 to 70.4)	44.3 (24.8 to 68.2)
	Min to Max	0.0 to 100.0	0.0 to 100.0	4.0 to 100.0	0.0 to 100.0
INR value, n(%)	n	435	343	185	963
	2-3	187 (43.0)	134 (39.1)	72 (38.9)	393 (40.8)
	<2	165 (37.9)	139 (40.5)	76 (41.1)	380 (39.5)
	>3	83 (19.1)	70 (20.4)	37 (20.0)	190 (19.7)
INR	n	435	343	185	963
	Mean (SD)	2.4 (1.0)	2.4 (1.2)	2.4 (1.0)	2.4 (1.1)
	Median (IQR)	2.2 (1.8 to 2.8)	2.1 (1.7 to 2.8)	2.2 (1.7 to 2.9)	2.2 (1.7 to 2.8)
	Min to Max	1.0 to 9.7	0.9 to 9.6	1.0 to 7.9	0.9 to 9.7

Table 13 :Event rates during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : ARGENTINA

Outcome	Cause	N	Events	Event rate /100 person-years	95% CI
All-cause death		844	52	6.52	(4.97 to 8.55)
	Cardiovascular death	844	23	2.88	(1.92 to 4.34)
	Non-Cardiovascular death	844	21	2.63	(1.72 to 4.04)
	Undetermined cause	844	8	1.00	(0.50 to 2.01)
Stroke/SE		844	12	1.51	(0.86 to 2.66)
Major bleed		844	10	1.26	(0.68 to 2.34)
Acute coronary syndrome		844	9	1.13	(0.59 to 2.18)
Congestive Heart Failure		844	28	3.58	(2.47 to 5.19)

Table 14: Cause of death during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : ARGENTINA

ARGENTINA				
Outcome	Cause	N	Events	%
Cardiovascular causes	Myocardial infarction	23	1	4.35
	Ischaemic stroke	23	3	13.04
	Congestive heart failure	23	9	39.13
	Sudden or unwitnessed death	23	6	26.09
	Other	23	4	17.39
Non-cardiovascular causes	Respiratory failure	21	5	23.81
	Infection/sepsis	21	6	28.57
	Malignancy	21	7	33.33
	Other	21	3	14.29

Table 15: Type of stroke during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset :ARGENTINA

OUTCOME	ARGENTINA		
	N	Events	%
Stroke(not including systemic embolism)	844	11	1.30
Primary Ischemic Stroke	844	8	0.95
Primary intracerebral hemorrhage*	844	1	0.12
<i>Intraventricular</i>	844	1	0.12
Undetermined	844	2	0.24

Table 16 : Mortality rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : ARGENTINA

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	14	13.86	0	-	-
1	104	100.12	3	3.00	(0.97 to 9.29)
2	190	182.07	8	4.39	(2.20 to 8.79)
3	199	190.08	10	5.26	(2.83 to 9.78)
4+	322	297.05	29	9.76	(6.78 to 14.05)
Unknown	15	14.70	2	13.60	(3.40 to 54.39)

**Table 17 : Stroke/SE rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : ARGENTINA**

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	14	13.86	0	-	-
1	104	100.12	0	-	-
2	190	181.11	3	1.66	(0.53 to 5.14)
3	199	187.58	3	1.60	(0.52 to 4.96)
4+	322	295.77	6	2.03	(0.91 to 4.52)
Unknown	15	14.70	0	-	-

Table 18 : Major bleeding rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : ARGENTINA

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	14	13.86	0	-	-
1	104	100.12	0	-	-
2	190	182.07	2	1.10	(0.28 to 4.39)
3	199	189.27	2	1.06	(0.26 to 4.23)
4+	322	294.01	6	2.04	(0.92 to 4.54)
Unknown	15	14.70	0	-	-